

Prothena Corporation plc Investor Relations Department 331 Oyster Point Blvd South San Francisco, CA 94080 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: PRTA	
Last Trade:	55.23
Trade Time:	4:00 PM ET Aug 17, 2017
Change:	-2.46 ♣ (- 4.264%)
Day Range	55.20 - 58.96
52-Week Range	40.58 - 69.53
Volume	209,887

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a latestage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

... (more)

Stock Performance



Press Releases [View all]

Aug 15, 2017

Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting

Aug 8, 2017

<u>Prothena Reports Second Quarter 2017</u> <u>Financial Results and Provides R&D Update</u>

Aug 1, 2017

<u>Prothena to Report Second Quarter 2017</u> <u>Financial Results on August 8</u>

Jul 5. 2017

Prothena Announces Initiation of Phase 2
PASADENA Study of PRX002/RG7935 in
Patients with Early Parkinson's Disease

Jun 12, 2017

Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer

Financials [View all]

Second Quarter Financial Results

Feb 27, 2017

Annual Report (10-K)

Mar 31, 2017

Proxy Statement (DEF 14A)

Aug 9, 2017

Quarterly Report (10-Q)

May 9, 2017

Quarterly Report (10-Q)

Nov 2, 2016

Quarterly Report (10-Q)